Phosphatidylserine and Prothrombin Antibodies, IgG and IgM

Also known as: APS/PT PAN

Clinical Use

Use

The presence of elevated and persistent antiphosphatidylserine (aPS) and prothrombin (PT) antibodies, specifically IgG and IgM, with or without lupus anticoagulant activity, may act as a risk marker for thrombosis in patients with certain autoimmune diseases such as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). This test may be useful when other antiphospholipid (aPL) antibody tests are negative, helping to document persistence of antibodies associated with these conditions.

Special Instructions

Not provided.

Limitations

The test is limited in its ability to distinguish between autoimmune disease types without clinical correlation. It may not detect all variations of anticardiolipin antibodies unless persistently elevated and supported with clinical signs of thrombotic disorders. Moreover, false positives could occur due to other coagulopathies or medication interference, emphasizing the need for comprehensive patient evaluation and history.

Test Details

New York Approved

Methodology

Immunoassay (ELISA)

Biomarkers

Phosphatidylserine and Prothrombin IgG

Protein

Phosphatidylserine and Prothrombin IgG

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

Phosphatidylserine and Prothrombin IgM

Protein

Phosphatidylserine and Prothrombin IgM

Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)

LOINC Codes

Result Codes

85359-8 - PS-prothrom cmplx IgG SerPl IA-aCnc
85358-0 - PS-prothrom cmplx IgM SerPl IA-aCnc

Result Turnaround Time

1-8 days

Specimen

Serum

Volume

0.5 mL

Minimum Volume

0.3 mL

Container

ARUP standard transport tube

Collection Instructions

Collect using a serum separator tube (SST) or a light blue sodium citrate tube. Ensure prompt separation from cells either immediately or within 2 hours of collection.